TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
- Authors:
- Alaa Refaat
- Ahmed Abd‑Rabou
- Asmaa Reda
-
Affiliations: Center for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12588, Egypt - Published online on: February 27, 2014 https://doi.org/10.3892/ol.2014.1922
- Pages: 1327-1332
This article is mentioned in:
Abstract
 |
 |
 |
|
Long JS and Ryan KM: New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene. 31:5045–5060. 2012. View Article : Google Scholar | |
|
Mellier G, Huang S, Shenoy K and Pervaiz S: TRAILing death in cancer. Mol Aspects Med. 31:93–112. 2010. View Article : Google Scholar | |
|
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Rieger J, Ohgaki H, Kleihues P and Weller M: Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol. 97:1–4. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, et al: MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One. 8:e568172013. View Article : Google Scholar : PubMed/NCBI | |
|
Szliszka E, Czuba ZP, Kawczyk-Krupka A, Sieron-Stoltny K, Sieron A and Krol W: Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells. Med Sci Monit. 18:BR47–BR53. 2012. View Article : Google Scholar | |
|
He Y, Wang JS, Zhang P, Zhang WJ, Huang QL and Hua ZC: Synergistic apoptotic effect of the combination of diosgenin and TRAIL on non-small-cell lung cancer cell line A549 evaluated with the Chou-Talalay method. Yao Xue Xue Bao. 48:45–51. 2013.(In Chinese). | |
|
Cai Y and Liu X, Huang W, Zhang K and Liu X: Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim Biophys Sin (Shanghai). 44:535–543. 2012. View Article : Google Scholar | |
|
Bernardi S, Secchiero P and Zauli G: State of art and recent developments of anticancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov. 7:207–217. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zauli G, Monasta L, Rimondi E, Vecchi Brumatti L, Davanzo R, Demarini S and Secchiero P: Levels of TNF-related apoptosis-inducing ligand (TRAIL) show a long-term stability in the breast milk of mothers of preterm infants. J Hum Lact. 29:350–353. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al: Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 5:171ra172013. View Article : Google Scholar | |
|
Strebel A, Harr T, Bachmann F, Wernli M and Erb P: Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry. 43:126–133. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN and Sycheva AM: Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis. 14:778–787. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:33–42. 2000. View Article : Google Scholar | |
|
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA and Lin Y: Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther. 7:1156–1163. 2008. View Article : Google Scholar | |
|
Kaufmann T, Strasser A and Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, et al: Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter. 14:588–595. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Emam H, Zhao QL, Furusawa Y, Refaat A, Ahmed K, Kadowaki M and Kondo T: Apoptotic cell death by the novel natural compound, cinobufotalin. Chem Biol Interact. 199:154–160. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer. Oncol Lett. 6:840–844. 2013. | |
|
Refaat A, Shahat A, Ehsan N, Yassin N, Hammouda F, Abou Tabl E and Ismail S: Phytochemical and biological activities of Crataegus sinaica growing in Egypt. Asian Pac J Trop Med. 3:257–261. 2010. View Article : Google Scholar | |
|
Moon DO, Asami Y, Long H, Jang JH, Bae EY and Kim BY: Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner. Toxicol In Vitro. 27:257–263. 2013.PubMed/NCBI | |
|
Yamaguchi H and Wang HG: CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 279:45495–45502. 2004. View Article : Google Scholar | |
|
Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S: 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis. 27:717–728. 2006. | |
|
Moon DO, Kang CH, Kang SH, Choi YH, Hyun JW, Chang WY, et al: Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx. Toxicol Appl Pharmacol. 259:87–95. 2012.PubMed/NCBI | |
|
Moon DO, Kim MO, Choi YH and Kim GY: Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther. 9:1583–1595. 2010. View Article : Google Scholar | |
|
Woo JS, Kim SM, Jeong CH, Ryu CH and Jeun SS: Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. Biochem Biophys Res Commun. 431:354–359. 2013. View Article : Google Scholar | |
|
Sung B, Ravindran J, Prasad S, Pandey MK and Aggarwal BB: Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem. 285:35418–35427. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh AP, Klocke BJ, Ballestas ME and Roth KA: CHOP potentially co-operates with FOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress. PLoS One. 7:e395862012. View Article : Google Scholar : PubMed/NCBI | |
|
Martín-Pérez R, Niwa M and López-Rivas A: ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis. 17:349–363. 2012. | |
|
Sung B, Prasad S, Ravindran J, Yadav VR and Aggarwal BB: Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med. 53:1977–1987. 2012. View Article : Google Scholar | |
|
Kannappan R, Ravindran J, Prasad S, et al: Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther. 9:2196–2207. 2010. View Article : Google Scholar | |
|
Wu GS, Kim K and el-Deiry WS: KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol. 465:143–151. 2000. | |
|
Sung B, Park B, Yadav VR and Aggarwal BB: Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem. 285:11498–11507. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Park EJ, Choi KS, Yoo YH and Kwon TK: Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs. 24:260–269. 2013. View Article : Google Scholar | |
|
Safa AR, Day TW and Wu CH: Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets. 8:37–46. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang P, Zhang J, Bellail A, Jiang W, Hugh J, Kneteman NM and Hao C: Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal. 19:2237–2246. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 22:954–965. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yerbes R, López-Rivas A, Reginato MJ and Palacios C: Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells. Cell Death Differ. 19:1908–1916. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kang D, Sun BK, Kim JH and Song JJ: TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex. Cell Signal. 25:372–379. 2013. View Article : Google Scholar | |
|
Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Elliott S, et al: Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res. 2:446–458. 2012.PubMed/NCBI | |
|
Jane EP, Premkumar DR and Pollack IF: Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-κB signaling pathway. Mol Cancer Ther. 10:198–208. 2011.PubMed/NCBI | |
|
Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM and Kurzrock R: Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 31:e137–e140. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, et al: p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway. Angiogenesis. 16:561–573. 2013.PubMed/NCBI | |
|
Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 20:911–928. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ciraolo E, Morello F and Hirsch E: Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem. 18:2674–2685. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A and Loeffler JS: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Alladina SJ, Song JH, Davidge ST, Hao C and Easton AS: TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res. 42:337–347. 2005. View Article : Google Scholar | |
|
Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 111:3322–3330. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA and Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54:3253–3259. 1994.PubMed/NCBI | |
|
Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Reed JC: Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34(Suppl 5): 9–19. 1997.PubMed/NCBI | |
|
Cristofanon S and Fulda S: ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis. 3:e4322012. View Article : Google Scholar : PubMed/NCBI | |
|
Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, et al: Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology. 57:625–636. 2013. View Article : Google Scholar | |
|
Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 97:7124–7129. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hussein MR, Haemel AK and Wood GS: Apoptosis and melanoma: molecular mechanisms. J Pathol. 199:275–288. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Yue P, Khuri FR and Sun SY: p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64:5078–5083. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Takimoto R and El-Deiry WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 19:1735–1743. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Guan B, Yue P, Clayman GL and Sun SY: Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol. 188:98–105. 2001. View Article : Google Scholar | |
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ and Cheng AL: Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol. 83:769–777. 2012. View Article : Google Scholar | |
|
Chen KF, Tai WT, Liu TH, Huang HP, Li YC, Shiau CW, et al: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res. 16:5189–5199. 2010. View Article : Google Scholar : PubMed/NCBI |
